Advertisement
UK markets close in 6 hours 30 minutes
  • FTSE 100

    8,107.55
    +28.69 (+0.36%)
     
  • FTSE 250

    19,810.28
    +208.30 (+1.06%)
     
  • AIM

    755.94
    +2.82 (+0.37%)
     
  • GBP/EUR

    1.1660
    +0.0004 (+0.03%)
     
  • GBP/USD

    1.2525
    +0.0014 (+0.12%)
     
  • Bitcoin GBP

    51,418.06
    +398.55 (+0.78%)
     
  • CMC Crypto 200

    1,389.85
    -6.68 (-0.48%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    83.72
    +0.15 (+0.18%)
     
  • GOLD FUTURES

    2,360.30
    +17.80 (+0.76%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,058.98
    +141.70 (+0.79%)
     
  • CAC 40

    8,045.16
    +28.51 (+0.36%)
     

The Quarterly Performances of GlaxoSmithKline’s Business Segments

The Quarterly Performances of GlaxoSmithKline’s Business Segments

GlaxoSmithKline’s (GSK) product portfolio is separated into three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. GlaxoSmithKline reported a rise in revenue at constant exchange rates across all three of its segments during the first quarter of 2018 compared to the first quarter of 2017. The Pharmaceuticals segment reported a 4% fall in YoY (year-over-year) revenue to ~4.0 billion British pounds during the first quarter, including a 2% rise in operating revenue offset by the 6% negative impact of foreign exchange.